SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Kiniksa Pharmaceuticals, Ltd. (KNSA) trades at a trailing P/E of 58.0, forward P/E of 38.6. Trailing earnings yield is 1.72%, forward earnings yield 2.59%. PEG 0.62 (Peter Lynch undervalued ≤1.0). Graham Number is $11.70.
Criteria proven by this page:
- VALUE (58/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 38.6 (down from trailing 58.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.62 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.72% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 2.59% as earnings recover.
- Analyst consensus target $55.67 (+18.6% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 69/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
58/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KNSA
Valuation Multiples
P/E (TTM)58.0
Forward P/E38.6
PEG Ratio0.62
Forward PEG0.62
P/B Ratio6.03
P/S Ratio5.05
EV/EBITDA38.3
Per Share Data
EPS (TTM)$0.80
Forward EPS (Est.)$1.22
Book Value / Share$7.65
Revenue / Share$9.13
FCF / Share$1.84
Yields & Fair Value
Earnings Yield1.72%
Forward Earnings Yield2.59%
Dividend Yield0.00%
Graham Number$11.70
SharesGrow IV$61.87 (+31.9%)
Analyst Target$55.67 (+18.6%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-26.4 |
0.00 |
-24.57 |
0.00 |
- |
| 2017 |
-9.7 |
-0.06 |
-7.05 |
0.00 |
- |
| 2018 |
-8.0 |
-0.11 |
-4.27 |
0.00 |
- |
| 2019 |
-3.7 |
0.26 |
2.65 |
0.00 |
- |
| 2020 |
-6.8 |
0.53 |
3.50 |
0.00 |
- |
| 2021 |
-5.1 |
0.43 |
4.36 |
20.94 |
- |
| 2022 |
5.7 |
-0.03 |
2.62 |
4.72 |
- |
| 2023 |
87.3 |
-0.94 |
2.80 |
4.55 |
- |
| 2024 |
-32.7 |
0.08 |
3.22 |
3.34 |
- |
| 2025 |
51.9 |
-0.22 |
5.39 |
4.52 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.74 |
$0.00 |
$-23.97M |
- |
| 2017 |
$-2.00 |
$0.00 |
$-64.87M |
- |
| 2018 |
$-3.49 |
$0.00 |
$-103.23M |
- |
| 2019 |
$-2.99 |
$0.00 |
$-161.87M |
- |
| 2020 |
$-2.61 |
$0.00 |
$-161.38M |
- |
| 2021 |
$-2.30 |
$38.54M |
$-157.92M |
-409.7% |
| 2022 |
$2.60 |
$220.18M |
$183.36M |
83.3% |
| 2023 |
$0.20 |
$270.26M |
$14.08M |
5.2% |
| 2024 |
$-0.60 |
$423.24M |
$-43.19M |
-10.2% |
| 2025 |
$0.75 |
$677.56M |
$59.01M |
8.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.22 |
$1.02 – $1.45 |
$914.11M |
$913.72M – $914.49M |
5 |
| 2027 |
$1.61 |
$1.17 – $1.89 |
$1.08B |
$1.05B – $1.1B |
5 |
| 2028 |
$2.26 |
$1.28 – $3.00 |
$1.24B |
$1.24B – $1.24B |
6 |
| 2029 |
$2.80 |
$2.74 – $2.87 |
$1.35B |
$1.33B – $1.38B |
4 |
| 2030 |
$4.42 |
$4.32 – $4.53 |
$1.51B |
$1.48B – $1.54B |
2 |
